Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to measure the impact of a discontinuous administration of oxytocin during the active phase of the 1st stage of labor on the neonatal morbidity rate.

The investigators hypothesize that discontinuation of oxytocin in the active phase of labor (from 6 cm) in women who received oxytocin in the latent phase or for an induction (before 4 cm of dilation) could reduce neonatal morbidity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Institut National de la Santé Et de la Recherche Médicale, France
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• With a term (≥37 WG) pregnancy

• Singleton pregnancy

• Fetus in cephalic presentation

• Women receiving oxytocin during the latent phase of the 1st stage of labor, before 4 cm of cervical dilatation, including women with an induction of labor using cervical ripening or oxytocin

• Speaking and reading French language

• Affiliated to social security

• Who have signed the consent form

Exclusion Criteria:

• Women with a scarred uterus

• Fetus with a congenital anomaly

• Fetal growth retardation <3rd percentile

• Having an abnormal fetal heart rate at randomization

• Maternal age < 18 years

• Participating in another trial involving medication